These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28942789)

  • 41. Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors.
    Mintz ML
    J Fam Pract; 2016 Dec; 65(12 Suppl):. PubMed ID: 28149983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SGLT2 inhibitors in the management of type 2 diabetes.
    Monica Reddy RP; Inzucchi SE
    Endocrine; 2016 Aug; 53(2):364-72. PubMed ID: 27270407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors.
    Fralick M; Martins D; Tadrous M; Gomes T
    Can J Hosp Pharm; 2022; 75(2):104-107. PubMed ID: 35387366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
    Goldenberg RM; Ahooja V; Clemens KK; Gilbert JD; Poddar M; Verma S
    Can J Diabetes; 2021 Apr; 45(3):291-302. PubMed ID: 33189580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pathophysiological explanation of cardiovascular benefits of sodium-glucose cotransporter-2 inhibitors by neurotrophic theory.
    Hristova M
    Med Hypotheses; 2017 May; 102():61-64. PubMed ID: 28478833
    [No Abstract]   [Full Text] [Related]  

  • 49. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
    Bardaweel S; Issa A
    J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefits, risks of SGLT2 inhibitors explored at session.
    Caffrey MK
    Am J Manag Care; 2014 Jul; 20(10 Spec No):E11. PubMed ID: 25830192
    [No Abstract]   [Full Text] [Related]  

  • 51. Dapagliflozin efficacy and safety: a perspective review.
    Anderson SL
    Ther Adv Drug Saf; 2014 Dec; 5(6):242-54. PubMed ID: 25436106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
    Simes BC; MacGregor GG
    Diabetes Metab Syndr Obes; 2019; 12():2125-2136. PubMed ID: 31686884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.
    Ito M; Tanaka T
    Intern Med; 2018 Aug; 57(15):2105-2114. PubMed ID: 29491318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SGLT2 inhibitors: the latest "new kids on the block"!
    Cefalu WT; Riddle MC
    Diabetes Care; 2015 Mar; 38(3):352-4. PubMed ID: 25715412
    [No Abstract]   [Full Text] [Related]  

  • 55. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 56. ACP Journal Club. Review: sodium-glucose cotransporter 2 inhibitors reduce HbA1c and weight but increase infections.
    Jaiswal G; Gandhi GY
    Ann Intern Med; 2014 Jan; 160(2):JC10. PubMed ID: 24445708
    [No Abstract]   [Full Text] [Related]  

  • 57. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review.
    Manoj A; Das S; Kunnath Ramachandran A; Alex AT; Joseph A
    Future Med Chem; 2020 Nov; 12(21):1961-1990. PubMed ID: 33124462
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk stratification of patients with diabetes and the role of sodium glucose co-transporter inhibitors 2 during Ramadan fasting.
    Adnan Z
    Diabetes Res Clin Pract; 2017 Sep; 131():217-218. PubMed ID: 28778048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sodium‑glucose cotransporter‑2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand?
    Vallianou NG; Tsilingiris D; Kounatidis D; Lempesis IG; Karampela I; Dalamaga M
    Pol Arch Intern Med; 2022 Oct; 132(10):. PubMed ID: 36094176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Renal aspects of sodium glucose cotransporter 2 inhibitors].
    Beaud F; Pruijm M; Humbert A; Burnier M; Zanchi A
    Rev Med Suisse; 2015 Feb; 11(463):488-92. PubMed ID: 25898456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.